Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04245150 · ClinicalTrials.gov registry record
Assessing the Impact of the Microbiome on Breast Cancer Radiotherapy Toxicity
A clinical trial, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- 23
- Enrollment target
NCT04245150: Completed study, sponsored by Case Comprehensive Cancer Center.
NCT04245150 is a clinical trial that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04245150 has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
Microorganisms in the human body (such as virus, bacteria, fungus) may have an important role in breast cancer side effects. In this study, microorganisms will be analyzed to determine which, if any,are present. It will then be determined if side effects from breast radiation are associated with these microorganisms. Understanding the association of microorganisms with side effects will allow the study team to look at strategies to reduce side effects for patients undergoing radiation to the breast.
Primary Outcome
Microbiome profile as assessed by stool sample. Sample analysis will be done via DNA extraction and rRNA gene sequencing of stool sample
Interventions
- OTHER Stool sample
- OTHER Skin Swab Sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-03-21 |
| Est. Completion | 2024-07-30 |
What the finished NCT04245150 record still lists
NCT04245150 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Stool sample is the first listed.
NCT04245150 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04245150 about?
NCT04245150 is a clinical study titled "Assessing the Impact of the Microbiome on Breast Cancer Radiotherapy Toxicity". Microorganisms in the human body (such as virus, bacteria, fungus) may have an important role in breast cancer side effects. In this study, microorganisms will be analyzed to determine which, if any,are present. It will then be determined if side effects from breast radiation are associated with the...
What is the current status of trial NCT04245150?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2019-03-21. Estimated completion is 2024-07-30.
What interventions are being tested in trial NCT04245150?
The interventions under investigation include: Stool sample (OTHER), Skin Swab Sample (OTHER).
Who is sponsoring clinical trial NCT04245150?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI